EGFR and nasopharyngeal carcinoma: The combination therapy involving ICIs and targeted therapy (anti- angiogenesis or EGFR inhibitors) as a second line or subsequent treatment for R/M NPC has exhibited the ability to extend PFS without a significant increase in AEs.